Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)

ClinicalTrials.gov ID: NCT00163514

Public ClinicalTrials.gov record NCT00163514. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial Designed to Assess the Efficacy and Safety of Ciclesonide Applied as a Nasal Spray at Three Dose Levels (200 Mcg, 100 Mcg, or 25 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 6-11 Years of Age

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.

Study identification

NCT ID
NCT00163514
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
636 participants

Conditions and interventions

Eligibility (public fields only)

Age range
6 Years to 11 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2004 (Type not available)
Primary completion
Jul 2005 (Actual)
Completion
Jul 2005 (Actual)
Last update posted
Dec 2, 2016

2004 – 2005

United States locations

U.S. sites
58
U.S. states
26
U.S. cities
55
Facility City State ZIP Site status
Altana Pharma/Nycomed Oxford Alabama 36203 —
Altana Pharma/Nycomed Huntington Beach California 92647 —
Altana Pharma/Nycomed Mission Viejo California 92691 —
Altana Pharma/Nycomed Newport Beach California CA 92660 —
Altana Pharma/Nycomed Orange California 92868 —
Altana Pharma/Nycomed Palmdale California 93551 —
Altana Pharma/Nycomed San Diego California 92120 —
Altana Pharma/Nycomed San Diego California 92123 —
Altana Pharma/Nycomed San Jose California 95117 —
Altana Pharma/Nycomed Stockton California 95207 —
Altana Pharma/Nycomed Walnut Creek, CA California 94598 —
Altana Pharma/Nycomed Coral Gables Florida 33134 —
Altana Pharma/Nycomed Ocala Florida 34471 —
Altana Pharma/Nycomed Atlanta Georgia 30342 —
Altana Pharma/Nycomed Gainesville Georgia 30501 —
Altana Pharma/Nycomed Savannah Georgia 31406 —
Altana Pharma/Nycomed Normal Illinois 61761 —
Altana Pharma/Nycomed Indianapolis Indiana 46208 —
Altana Pharma/Nycomed Dubuque Iowa 52001 —
Altana Pharma/Nycomed Overland Park Kansas 66210 —
Altana Pharma/Nycomed Metairie Louisiana 70001 —
Altana Pharma/Nycomed Shreveport Louisiana 71130 —
Altana Pharma/Nycomed Rockville Maryland 20850 —
Altana Pharma/Nycomed Wheaton Maryland 20902 —
Altana Pharma/Nycomed North Dartmouth Massachusetts 02747 —
Altana Pharma/Nycomed Minneapolis Minnesota 55402 —
Altana Pharma/Nycomed Jefferson City Missouri 65101 —
Altana Pharma/Nycomed Rolla, Mo Missouri 65401 —
Altana Pharma/Nycomed St Louis Missouri 63141 —
Altana Pharma/Nycomed Papillion Nebraska 68046 —
Altana Pharma/Nycomed Brick New Jersey 08724 —
Altana Pharma/Nycomed Skillman New Jersey 08558 —
Altana Pharma/Nycomed Liverpool New York 13088 —
Altana Pharma/Nycomed Raleigh North Carolina 27607 —
Altana Pharma/Nycomed Canton Ohio 44718 —
Altana Pharma/Nycomed Cincinnati, OH Ohio 45231 —
Altana Pharma/Nycomed Sylvania Ohio 43560 —
Altana Pharma/Nycomed Medford Oregon 97504 —
Altana Pharma/Nycomed Portland Oregon 97213 —
Altana Pharma/Nycomed Easton Pennsylvania 18045 —
Altana Pharma/Nycomed Hershey Pennsylvania 17033 —
Altana Pharma/Nycomed Upland Pennsylvania 19013 —
Altana Pharma/Nycomed Charleston South Carolina 29407 —
Altana Pharma/Nycomed Charleston South Carolina 29414 —
Altana Pharma/Nycomed Moncks Corner South Carolina 29461 —
Altana Pharma/Nycomed Spartanburg South Carolina 29307 —
Altana Pharma/Nycomed Austin Texas 78750 —
Altana Pharma/Nycomed El Paso Texas 79925 —
Altana Pharma/Nycomed Fort Worth Texas 76132 —
Altana Pharma/Nycomed Friendswood Texas 77546 —
Altana Pharma/Nycomed Houston Texas 77054 —
Altana Pharma/Nycomed Katy Texas 77450 —
Altana Pharma/Nycomed Salt Lake City Utah 84037 —
Altana Pharma/Nycomed South Burlington Vermont 05403 —
Altana Pharma/Nycomed Burke Virginia 22015 —
Altana Pharma/Nycomed Richmond Virginia 23219 —
Altana Pharma/Nycomed Richmond Virginia 23226 —
Altana Pharma/Nycomed Spokane Washington 99202 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00163514, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 2, 2016 · Synced Oct 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00163514 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →